Marizyme, Inc. · OTC:MRZM
Marizyme — Biotech Showcase 2021
9 slides from Marizyme's conference presentation, Feb 26, 2021
Slide 1: Marizyme Biotech Showcase 2021 Presentation Script
Marizyme Biotech Showcase 2021 Presentation Script January 2021 SLIDE 1 - Title Talk. Hello my name is Dr. Neil Campbell, and | am the President and CEO of Marizyme. My contact details are at the bottom of the slide. | thank you for your interest today in the company. This presentation and my commen
Slide 2: Marizyme's Current Structure
SLIDE 6 — Marizyme’s Current Structure. Marizyme is building its business by developing and commercializing medical devices, therapeutics and related products that focus on cellular protection and enhancement in a wide range of disorders and diseases. Marizyme currently has 2 platform-based, wholly-
Slide 3: Cellular Protection and SOMA Technology Platform
understanding the key drivers promoting cell health and enhancement such as: - maintaining cell viability - protecting cell function - promoting cell structural integrity - supporting cell-to-cell communications - and maintaining proper tissue architecture and function SLIDE 9 — Science & Technology
Slide 4: Coronary Artery Bypass Grafting (CABG)
SLIDE 12 - Coronary Artery Bypass Grafting (CABG) - CABG involves the constructing of an alternative path to bypass occluded arteries and restore blood flow to the patient; - Saphenous vein grafts are the most common and are taken from leg veins as you can see from the graphic on the slide; - All sa
Slide 5: DuraGraft - Intraoperative Endothelial Damage and Graft Disease
SLIDE 14 — DuraGraft — Intraoperative Endothelial Damage and Graft Disease. - More specifically, the ischemic damage to the vein graft can result in: - repeat revascularization procedures; - possibilities of myocardial infarction; - re-admission due to complications post-surgery; - angina; - poorer
Slide 6: DuraGraft Clinical Data Set - VA Boston Healthcare
SLIDE 17 - DuraGraft Clinical Data 1 Set - VA Boston Healthcare. - In our first study conducted at the VA Boston, there were 2,436 CABG patients in a retrospective design of DuraGraft vs. Standard of Care. - there were durable reductions in long-term clinical events over a period of 3 to 14 years; -
Slide 7: Marizyme's Commercial Approach
SLIDE 20 — Marizyme’s Commercial Approach. - The great news about platform technologies is there are many shots on goal. The not so great news is there are multiple options to pursue. - Marizyme will look at multiple options as a way to de-risk execution risks with options for commercialization both
Slide 8: DuraGraft vs. Standard of Care Buffers
SLIDE 23 — DuraGraft vs. Stand of Care Buffers. - As we enter 2021 with a focused commercialization plan for DuraGraft outside of the United States -- you can see here on the right of the slide — THE SIDE-BY-SIDE COMPARISON DuraGraft vs. Standard of Care. SLIDE 24 — DuraGraft Commercial Focus in 202
Slide 9: Summary Section Slide
SLIDE 27 - Summary Section Slide. SLIDE 28 —- Summary — Marizyme’s Value Proposition. - Marizyme is an integrated life science company focusing on preserving and enhancing cellular function for a variety of disorders and diseases. - Our initial focus is on the cardiovascular space. SLIDE 29 —- Summa